FY2025 Earnings Estimate for Acasti Pharma Inc. Issued By HC Wainwright (NASDAQ:ACST)

Acasti Pharma Inc. (NASDAQ:ACST) – Investment analysts at HC Wainwright lifted their FY2025 EPS estimates for Acasti Pharma in a research note issued on Monday, July 1st. HC Wainwright analyst O. Livnat now expects that the biopharmaceutical company will post earnings of ($1.14) per share for the year, up from their previous forecast of ($1.29). The consensus estimate for Acasti Pharma’s current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Acasti Pharma’s FY2026 earnings at ($0.76) EPS and FY2027 earnings at ($0.83) EPS.

Acasti Pharma (NASDAQ:ACST) last announced its earnings results on Friday, June 21st. The biopharmaceutical company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.30.

Acasti Pharma Trading Up 1.8 %

Shares of ACST stock opened at $2.90 on Wednesday. Acasti Pharma has a 12 month low of $1.72 and a 12 month high of $3.84. The stock has a market cap of $27.26 million, a P/E ratio of -2.01 and a beta of 1.55. The company has a 50 day simple moving average of $2.93 and a two-hundred day simple moving average of $2.95.

About Acasti Pharma

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.